Typically, retail investors do not invest in penny stocks. Penny stocks are stocks that have shares that are under $5.00 in price. These stocks can be $1.00 on any given day and can fly all the way up to $5.00 the following day. That said, just as quickly as they make that move, they can drop all the way back down to $1.00 the day after that. They are amazingly volatile.
So, it’s simple to see that it would be almost crazy to “invest” in them. At the same time, some companies do have “potential” and need to have a closer look-at as they could be the next penny stock to grow over $5.00 and keep their gains. Those companies might be ready to execute on their corporate plans and “bring home the bacon,” if you will… It does happen.
When you’re “investing,” you’re taking a buy and hold approach to stock trading. If you’ve heard the term “swing trading,” it’s not exactly the same. In a swing trade, you’re holding on to a stock for a short amount of time. This could be a month, a week, or maybe just over-night. If that trade turns into longer than a month, you’re looking at more of an investment.
In 2020, penny stocks have been buzzing as time and time again, they showed themselves to make crazy gains in the short-term. It is just one industry/sector either. These stocks have come from all over while exhibiting inexpensive shares can hold serious potential if the right news creates a momentum catalyst. Below you’ll find a handful of penny stocks that could be breakout ready after huge news.
Your New No. 1 Top Penny Stock To Watch This This Week: Myomo, Inc. (MYO)
Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace orthosis product used for supporting a patient’s weak or paralyzed arm to enable and enhance functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.
Myomo, Inc. announced that new published research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “Despite long-standing traumatic brain injury, meaningful improvements in motor function were observed.”
The Case Report in the Journal of Rehabilitation and Assistive Technologies Engineering (RATE), a peer-reviewed interdisciplinary journal, studied a 42-year-old female, 29.5 years post-traumatic brain injury with diminished motor control/coordination and learned nonuse of the right arm. The research consisted of 9 weeks of in-clinic training followed by 9 weeks of at-home use. It was funded by the U.S. Department of Defense through an award to Dr. Stefania Fatone at the Northwestern University Feinberg School of Medicine in Chicago and conducted by a research team at the Louis Stokes Cleveland VA Medical Center led by Dr. Svetlana Pundik.
The report can be found here: https://journals.sagepub.com/doi/full/10.1177/2055668320921067.
The study reports “During in-clinic training, active range of motion, tone, muscle power, Fugl-Meyer, box and blocks test, and Chedoke assessment score improved. During the home-use phase, decrease in tone was maintained and all other outcomes declined but were still better upon study completion than baseline.”
Lead author Svetlana Pundik, MD, MSc, Brain Plasticity and Neuro Recovery Laboratory, Louis Stokes Cleveland VA Medical Center, said “This individual had a very limited use of her arm before intervention with the device. In addition to the therapeutic benefits we measured, the patient’s caregivers reported functional improvement in her home setting. It is very heartwarming to see these improvements in a person even this many years after injury. This research is continuing now with a larger population of patients.”
Paul R. Gudonis, Myomo CEO, said “MyoPro not only extends the limited therapy time available in the clinic to continue in the home, it may also restore a person’s ability to perform activities of daily living such as feeding one’s self and performing light household tasks. As a result, users see an improved quality of life, some may return to work, and they may reduce their overall healthcare costs.”
Your New No. 2 Top Penny Stock To Watch This This Week: Safe-T Group Ltd.
Safe-T Group Ltd. (Nasdaq: SFET) develops and markets cyber security solutions in Israel, North America, the Asia-Pacific, Africa, Europe, and internationally. The company offers on-demand software defined perimeter solutions, which protect access to data and services by separating the access layer from the authentication layer, as well as by segregating internal networks and granting access only to authorized users; and software-defined access solutions that controls and secures data exchange, as well as prevents data exfiltration, leakage, malware, ransomware, and fraud. It serves customers in healthcare, financial services, insurance, retail, manufacturing, law firms, and defense and law enforcement industries, as well as governments and education institutions.
Safe-T® Group Ltd. provided an estimated revenue range for the second quarter of 2020 and for the six-month period ended June 30, 2020.
On a preliminary basis, Safe-T expects to report revenue for the six-month period ended June 30, 2020 in the range of $2.15 million to $2.2 million, an increase in the range of 162% to 168%, respectively, compared to $0.821 million during the equivalent period in 2019. On a preliminary basis, Safe-T’s second quarter 2020 revenue is expected to be in the range between $1.05 million to $1.1 million, an increase in the range of 166% to 179%, respectively, compared to $0.394 million in the second quarter of 2019.
Also, Safe-T reports that since the beginning of the second quarter of 2020, it has received gross proceeds in excess of $12 million from sale of equity securities in offerings completed during April 2020, as well as a result of exercise of warrants since then. These amounts significantly improved Safe-T’s cash position and will enable the Company to focus on the execution of its business strategy.
Safe-T expects to release the full, unaudited second quarter and first half results by August 31, 2020.
The above information reflects preliminary estimates with respect to certain of the Company’s second quarter and the first half of 2020 results, based on currently available information. The Company is providing ranges, rather than specific amounts, for these preliminary estimates primarily because the financial close process and review are not yet complete and, as a result, the Company’s final results upon completion of its closing process and review may vary from the preliminary estimates.
Your New No. 3 Top Penny Stock To Watch This This Week: BELLUS Health Inc.
BELLUS Health Inc. (Nasdaq: BLU), a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus.
BELLUS Health Inc. announced topline results from its Phase 2 RELIEF trial of BLU-5937 in patients with refractory chronic cough.
The Phase 2 RELIEF trial of BLU-5937 did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested. A clinically meaningful and highly statistically significant placebo-adjusted reduction in cough frequency was achieved in a pre-specified sub-group of high cough count patients (all patients at or above the baseline median average of 32.4 coughs per hour).
BLU-5937 was also observed to be well tolerated with no serious adverse events reported and no withdrawals due to treatment-related adverse events at any dose. Taste effects, including taste alteration and partial taste loss, were infrequent at all dose levels (6.5%, 9.8%, 10% and 8.6% at 25mg BID, 50mg BID, 100mg BID and 200mg BID, respectively, versus 4.9% on placebo) and mostly mild in nature. No patients reported complete taste loss. There were no clinically meaningful changes in vital signs, electrocardiogram or clinical laboratory values.
“In the RELIEF trial, we observed data that we believe is competitive within the P2X3 class, including the reduction in cough frequency shown in patients with higher cough counts and a low taste effect. While we had hoped to see more response in the lower cough patients, BLU-5937 and other P2X3 antagonists may have the most benefit in patients with a greater disease burden,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “We believe the Phase 2 data support moving BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020.”
“Currently, there are no approved treatments for refractory chronic cough, a condition that affects the quality of life of millions of patients globally. BELLUS Health was able to show clinically and statistically meaningful reductions in cough count in patients with higher baseline cough count, which may be the best available clinical indicator of cough hypersensitization via the P2X3 pathway. In addition, BLU-5937’s high selectivity resulted in a favorable tolerability profile with little reported taste disturbance,” said Dr. Jaclyn Smith, Professor of Respiratory Medicine at the University of Manchester in the United Kingdom and an Honorary Consultant at the University Hospital of South Manchester NHS Foundation Trust, and Chair of BELLUS Health’s Clinical Advisory Board. “The RELIEF Phase 2 data set the stage for the further development of BLU-5937 and I look forward to continuing to work on the program.”